Distinct and Recognisable Muscle MRI Pattern in a Series of Adults Harbouring an Identical GMPPB Gene Mutation.

BACKGROUND AND PURPOSE Mutations in the GMPPB gene affect glycosylation of α-dystroglycan, leading to varied clinical phenotypes. We attempted to delineate the muscle MR imaging spectrum of GMPPB-related Congenital Myasthenic syndrome (CMS) in a single-center cohort study. OBJECTIVE To identify the distinct patterns of muscle involvement in GMPPB gene mutations. METHODS We analyzed the muscle MR images of 7 genetically proven cases of GMPPB dystroglycanopathy belonging to three families and studied the potential qualitative imaging pattern to aid in clinico -radiological diagnosis in neuromuscular practice. All individuals underwent muscle MRI (T1, T2, STIR/PD Fat sat. sequences in 1.5 T machine) of the lower limbs. Qualitative assessment and scoring were done for muscle changes using Mercuri staging for fibro-fatty replacement on T1 sequence and Borsato score for myoedema on STIR sequence. RESULTS All patients were of South Indian origin and presented as slowly progressive childhood to adult-onset fatigable limb-girdle muscle weakness, elevated creatine kinase level, and positive decrement response in proximal muscles. Muscle biopsy revealed features of dystrophy. All patients demonstrated identical homozygous mutation c.1000G >  A in the GMPPB gene. MRI demonstrated early and severe involvement of paraspinal muscles, gluteus minimus, and relatively less severe involvement of the short head of the biceps femoris. A distinct proximo-distal gradient of affliction was identified in the glutei, vasti, tibialis anterior and peronei. Also, a postero-anterior gradient was observed in the gracilis muscle. CONCLUSION Hitherto unreported, the distinctive MR imaging pattern described here, coupled with relatively slowly progressive symptoms of fatigable limb-girdle weakness, would facilitate an early diagnosis of the milder form of GMPPB- dystroglycanopathy associated with homozygous GMPPB gene mutation.

[1]  E. Malfatti,et al.  Phenotypic Spectrum of Myopathies with Recessive Anoctamin-5 Mutations. , 2020, Journal of neuromuscular diseases.

[2]  S. Chen,et al.  Lysosomal degradation of GMPPB is associated with limb‐girdle muscular dystrophy type 2T , 2019, Annals of clinical and translational neurology.

[3]  F. Cui,et al.  Limb-girdle muscular dystrophy due to GMPPB mutations: A case report and comprehensive literature review , 2019, Bosnian journal of basic medical sciences.

[4]  G. Comi,et al.  Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study , 2018, Orphanet Journal of Rare Diseases.

[5]  K. Bushby,et al.  Mobility shift of beta-dystroglycan as a marker of GMPPB gene-related muscular dystrophy , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  E. Bertini,et al.  MRI in sarcoglycanopathies: a large international cohort study , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  Zhen-an Zhu,et al.  Novel mutations in the C-terminal region of GMPPB causing limb-girdle muscular dystrophy overlapping with congenital myasthenic syndrome , 2017, Neuromuscular Disorders.

[8]  B. Schoser,et al.  Two patients with GMPPB mutation: The overlapping phenotypes of limb‐girdle myasthenic syndrome and limb‐girdle muscular dystrophy dystroglycanopathy , 2016, Muscle & nerve.

[9]  Wotu Tian,et al.  Limb-girdle congenital myasthenic syndrome in a Chinese family with novel mutations in MUSK gene and literature review , 2016, Clinical Neurology and Neurosurgery.

[10]  M. Cossée,et al.  Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T) , 2016, Neurology: Genetics.

[11]  F. Muntoni,et al.  Clinical features of the myasthenic syndrome arising from mutations in GMPPB , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  T. Yousry,et al.  Muscle magnetic resonance imaging in congenital myasthenic syndromes , 2016, Muscle & nerve.

[13]  K. Bushby,et al.  This Work Is Licensed under a Creative Commons Attribution 4.0 International License Mutations in Gmppb Cause Congenital Myasthenic Syndrome and Bridge Myasthenic Disorders with Dystroglycanopathies , 2022 .

[14]  R. Maselli,et al.  Congenital Myasthenic Syndrome due to DOK7 mutations in a family from Chile , 2015, European journal of translational myology.

[15]  D. MacArthur,et al.  Expanding the phenotype of GMPPB mutations. , 2015, Brain : a journal of neurology.

[16]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[17]  E. Rushing,et al.  Congenital Myasthenic Syndrome caused by mutations in DPAGT , 2015, Neuromuscular Disorders.

[18]  E. Stålberg,et al.  Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. , 2014, Brain : a journal of neurology.

[19]  S. Frank,et al.  Skeletal muscle MRI of the lower limbs in congenital muscular dystrophy patients with novel POMT1 and POMT2 mutations , 2014, Neuromuscular Disorders.

[20]  D. MacArthur,et al.  Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan. , 2013, American journal of human genetics.

[21]  H. Urbach,et al.  Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs , 2005, Journal of Neurology.

[22]  E. Mercuri,et al.  Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1) , 2002, Neuromuscular Disorders.